Hepatocellular Carcinoma: Self‐Activated Cascade‐Responsive Sorafenib and USP22 shRNA Co‐Delivery System for Synergetic Hepatocellular Carcinoma Therapy (Adv. Sci. 5/2021)

Resistance to sorafenib remains one of the biggest concerns for hepatocellular carcinoma treatment. In article number 2003042, Xiao Xu, Jiajia Xiang, and co-workers developed a self-activated sorafenib and USP22 shRNA codelivery nanoplatform (Gal-SLP) to reverse cancer stemness and sensitive cancer cells to sorafenib. Gal-SLP releases USP22 shRNA efficiently and enhances the intracellular sorafenib accumulation in cancer cells. Gal-SLP exhibits potent antitumor efficiency in a sorafenibinsensitive patient-derived xenograft (PDX) model.